Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Rev Neurother. 2009 Dec;9(12):1781-9. doi: 10.1586/ern.09.117.

Current strategies in the treatment of Parkinson's disease and a personalized approach to management.

Author information

1
Neurological Institute at Columbia University Medical Center, 710 W168th St, 3rd floor, New York, NY 10032, USA. nd2284@mail.cumc.columbia.edu

Abstract

Parkinson's disease is a progressive, neurodegenerative disorder affecting millions of people worldwide. Given the aging population, the prevalence of the disease is expected to increase substantially. The mainstay of treatment has been dopamine replacement therapy with carbidopa, levodopa, dopamine agonists, monoamine oxidase type B inhibitors, catechol-O-methyltransferase inhibitors and amantadine. Nonmotor features, such as cognitive impairment, mood disorders, autonomic dysfunction, gastrointestinal and genitourinary dysfunction, have a substantial impact on Parkinson's disease patients and their quality of life. This review will provide an overview on medications currently available for management of both motor and nonmotor symptoms of Parkinson's disease. Focus will be placed on recent and evolving studies evaluating symptomatic and neuroprotective effects of medications, and how such studies may impact the future management of Parkinson's disease.

PMID:
19951137
DOI:
10.1586/ern.09.117
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center